NRx Pharmaceuticals (NASDAQ:NRXP) Releases FY 2023 Earnings Guidance

NRx Pharmaceuticals (NASDAQ:NRXP) updated its FY 2023 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of -0.400–0.400 for the period, compared to the consensus estimate of -0.370. The company issued revenue guidance of -.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ:NRXP opened at $0.47 on Friday. The company has a 50 day moving average price of $0.47 and a 200 day moving average price of $0.38. NRx Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $1.20.

NRx Pharmaceuticals’s stock is scheduled to reverse split before the market opens on Tuesday, April 2nd. The 1-10 reverse split was announced on Tuesday, April 2nd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, April 2nd.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new position in NRx Pharmaceuticals in the 1st quarter worth approximately $25,000. HRT Financial LP acquired a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $29,000. Citigroup Inc. boosted its stake in NRx Pharmaceuticals by 355.1% in the 1st quarter. Citigroup Inc. now owns 15,208 shares of the company’s stock worth $37,000 after purchasing an additional 11,866 shares during the period. Bank of America Corp DE boosted its stake in NRx Pharmaceuticals by 10,884.4% in the 4th quarter. Bank of America Corp DE now owns 35,809 shares of the company’s stock worth $40,000 after purchasing an additional 35,483 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.